Abstract
Platelets are dynamic blood cells that form life-threatening thrombi in response to a variety of pathological conditions such as atherosclerosis, diabetes, metastatic cancer, sickle cell disease and obesity. These thrombi can lead directly to myocardial infarction (MI), stroke and other thrombotic events that contribute to over a million deaths every year in the United States. Even though multiple, effective drugs have been developed to combat these pathologies by antagonizing platelet receptors and their ligands, clinical use of these drugs can result in serious bleeding consequences. With the advent of increasingly powerful and accessible systems biology approaches, however, new opportunities are available to identify novel platelet targets and elucidate potentially safer antiplatelet strategies. Here we provide an overview of some of these exciting systems approaches ranging from genomics to aptamer discovery and emphasize the importance of identifying and exploiting novel platelet targets for therapeutic benefit.
Keywords: Aptamer, genomics, integrin, P2Y12, platelet, proteomics, signaling, thrombosis, antiplatelet therapy, aptamers
Current Drug Targets
Title: Big Science for Small Cells: Systems Approaches for Platelets
Volume: 12 Issue: 12
Author(s): Stephen P. Holly and Leslie V. Parise
Affiliation:
Keywords: Aptamer, genomics, integrin, P2Y12, platelet, proteomics, signaling, thrombosis, antiplatelet therapy, aptamers
Abstract: Platelets are dynamic blood cells that form life-threatening thrombi in response to a variety of pathological conditions such as atherosclerosis, diabetes, metastatic cancer, sickle cell disease and obesity. These thrombi can lead directly to myocardial infarction (MI), stroke and other thrombotic events that contribute to over a million deaths every year in the United States. Even though multiple, effective drugs have been developed to combat these pathologies by antagonizing platelet receptors and their ligands, clinical use of these drugs can result in serious bleeding consequences. With the advent of increasingly powerful and accessible systems biology approaches, however, new opportunities are available to identify novel platelet targets and elucidate potentially safer antiplatelet strategies. Here we provide an overview of some of these exciting systems approaches ranging from genomics to aptamer discovery and emphasize the importance of identifying and exploiting novel platelet targets for therapeutic benefit.
Export Options
About this article
Cite this article as:
P. Holly Stephen and V. Parise Leslie, Big Science for Small Cells: Systems Approaches for Platelets, Current Drug Targets 2011; 12 (12) . https://dx.doi.org/10.2174/138945011797635795
DOI https://dx.doi.org/10.2174/138945011797635795 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fractalkine/CX3CR1 Signalling in Chronic Pain and Inflammation
Current Pharmaceutical Biotechnology Human Anthrax as a Re-Emerging Disease
Recent Patents on Anti-Infective Drug Discovery Inhibition of Candida rugosa Lipase by Secondary Metabolites Extracts of Three Algerian Plants and their Antioxydant Activities
Current Enzyme Inhibition Out-of-Hospital Cardiac Arrest –Optimal Management
Current Cardiology Reviews Recent Advances in Ozonation of Vegetable Oils
Recent Patents on Materials Science Arterial Stiffness, Cognitive Dysfunction and Adherence to Antihypertensive Agents. Is there a Link to Hypertensive Patients?
Current Vascular Pharmacology Pentraxins and Atherosclerosis: The Role of PTX3
Current Pharmaceutical Design Development of Anti-Atherosclerosis Therapy Based on the Inflammatory and Proliferative Aspects of the Disease
Current Pharmaceutical Design The Long Run: Neuroprotective Effects of Physical Exercise on Adult Neurogenesis from Youth to Old Age
Current Neuropharmacology Blood Serum Atherogenicity and Coronary Artery Calcification
Current Pharmaceutical Design Homocysteine and Non-Cardiac Vascular Disease
Current Pharmaceutical Design Mechanisms and Medical Management of Exercise Intolerance in Hypertrophic Cardiomyopathy
Current Pharmaceutical Design Carotid Artery Atherosclerosis: What is the Evidence for Drug Action?
Current Pharmaceutical Design A Review on Pharmacological and Clinical Aspects of Linum usitatissimum L.
Current Drug Discovery Technologies Endothelial Progenitor Cells and In-stent Restenosis
Current Stem Cell Research & Therapy Genetics of Atherosclerosis in Murine Models
Current Drug Targets Cardiac Metabolism in Myocardial Ischemia
Current Pharmaceutical Design Update on the Pharmacological Treatment of Alzheimers Disease
Current Neuropharmacology Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives
Current Vascular Pharmacology Nitric Oxide and Dietary Factors: Part II Cholesterol, Fat, Amino Acids,Proteins and Carbohydrate
Vascular Disease Prevention (Discontinued)